An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance

Liver Transplantation

Volumn 13, Issue 10, 2007, Pages 1422-1427

  Humar, Atul ^a   Washburn, Kenneth ^b   Freeman, Richard ^c   Paya, Carlos V ^d   Mouas, Houria ^e   Alecock, Emma ^f   Razonable, Raymund R ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d Mayo Clinic   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE KIDNEY FUNCTION RELATION; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; INCIDENCE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 35448937998     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21266     Document Type: Article

References (20)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
2. Bizollon T, Ducerf C, Trepo C, Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999;44: 575-578.
3. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M. et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
5. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
6. Yoshikawa, T. Human herpesvirus-6 and -7 infections in transplantation. Pediatr Transplant 2003:7:11-17.
7. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461-466.
8. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002;35:974-981.
9. Singh N, Husain S, Carrigan DR, Knox KK, Week KE, Wagener MM, Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002;16:92-96.
10. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.
11. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003;10:12-16.
12. Singh N, Gayowski T, Wagener MM, Marino I R. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.
13. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003;98:167-174.
14. Hezode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999;30:775-778.
15. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000;6:570-574.
16. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
17. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005;192:1331-1339.
18. Tong CY, Bakran A, Williams H, Cuevas LE, Peiris JS, Hart CA. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol 2001;64: 29-34.
19. Kimball P, Verbeke S, Shiffman M. HCV core protein augments cyclosporine immunosuppression. Transplant Proc 2005;37:652-653.
20. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hezode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74:1103-1109.